Private and employer-sponsored plans: These tend to vary the most
Standard titration protocol from clinical trials The Phase 2 NEJM trial used the following escalation schedule for the 12 mg dose group: Weeks 1 through 4: 2 mg once weekly (subcutaneous) Weeks 5 through 8: 4 mg once weekly Weeks 9 through 12: 8 mg once weekly Week 13 and beyond: 12 mg once weekly (maintenance dose) For the 8 mg target dose, the schedule was: Weeks 1 through 4: 2 mg once weekly Weeks 5 through 8: 4 mg once weekly Week 9 and beyond: 8 mg once weekly (maintenance dose) These titration schedules are not suggestions
Ahmed M, Arun A, Pfeferman M, Rashedi S, Zuin M, Secemsky E, Goldhaber S, Monreal M, Jimenez D, Piazza G, Krumholz H , Bikdeli B
Research Applications & Usage Information IGF-1 LR3 (1 mg) is commonly incorporated into laboratory and preclinical research involving: IGF-1 receptor activation and binding affinity studies Myoblast and muscle cell culture experiments Cellular proliferation and differentiation assays Protein synthesis and anabolic signaling research Intracellular signaling pathway analysis (e.g., PI3K/Akt, MAPK/ERK) Comparative evaluation of native IGF-1 versus long-acting analogs Metabolic regulation and glucose-uptake research models Tissue growth and regenerative pathway investigations All applications are investigational and limited to in vitro or preclinical research settings